PRME | Page 1 | RegMed Investors

utility

header_second

RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

Login Sign up now Not now

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

4.04

0.34

(34.00%)

content_middle

Previous Close:

3.70

52wk Range:

1.11 - 6.94

Market Capitalization:

0.00M

Shares Outstanding:

0.00M

content_right

August 1, 2025 - 4:52pm | Out and About, Research Notes, Out and About, Financings
RegMedInvestors (RMi) Finance note: Prime Medicine (PRME) closes 43.7 M share offering at $3.30

PRME
July 30, 2025 - 7:26pm | Out and About, Out and About, Financings
RegMedInvestors (RMi) Finance note: Prime Medicine (PRME) proposes offering

PRME
December 3, 2024 - 4:32pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q3
RegMed Investors (RMi) - Q3/24 Cell and Gene Therapy Earnings Scorecard Results

SAGE, MDXG
February 15, 2024 - 7:15am | Out and About, Research Notes, Out and About, Financings
RegMed Investors (RMi) Research Note: Prime Medicine (PRME) Prices 19million share offering at $6.25

Prime Medicine (PRME)
July 31, 2023 - 7:19am | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q2
RegMed Investors (RMi) Research Note: Q2/2023 earnings reporting date announcements

MDXG, BPMC, VCEL, ALNY, EDIT, NTLA, BEAM, VERV, PRME, CRSP
May 27, 2023 - 12:37pm | Out and About, Research Notes, Out and About, Earnings Alert, Earnings, Earnings Q1
RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes

SGMO, SAGE, MDXG, AXGN
April 10, 2023 - 4:40pm | Out and About, Research Notes, Out and About, Earnings, Earnings Q4
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting

SAGE, RARE, CRSP, EDIT, VCEL, NTLA, QURE, MESO, BEAM, VYGR, KDNY, FIXX, CRBU, AGEN, AXGN, VSTM, BLUE, ADVM, BCLI
January 9, 2023 - 1:49pm | Out and About, Research Notes, Out and About
RegMed Investors (RMi) Research Note: News related to JPM23

IONS, EDIT, VYGR, BLFS, MDXG, SLDB, AXGN, BEAM, ALNY, SAGE
October 20, 2022 - 2:10pm | Out and About, Research Notes, Out and About
Prime Medicine (PRME) a gene editing company has raised $175 million selling 1.4 million shares in the middle of its $17-$19 price range in its IPO

PRME

footer

© 2015 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.